

1 DIMITRI D. PORTNOI (S.B. # 282871)
dportnoi@omm.com
2 KYLE M. GROSSMAN (S.B. # 313952)
kgrossman@omm.com
3 O'MELVENY & MYERS LLP
400 S. Hope Street, 18th Floor
4 Los Angeles, CA 90071
Telephone: (213) 430-6000
5 Facsimile: (213) 430-6407

6 *Attorneys for Defendants Kaiser Foundation*
Health Plan, Inc.; Kaiser Foundation Hospitals;
7 *The Permanente Medical Group, Inc.; Southern*
California Permanente Medical Group; and
8 *Colorado Permanente Medical Group, P.C.*

9
10
11 **UNITED STATES DISTRICT COURT**
12 **EASTERN DISTRICT OF CALIFORNIA**
13

14
15 UNITED STATES OF AMERICA et al. ex
rel. JEFFREY MAZIK,

16
17 Plaintiffs,

18 v.

19 KAISER FOUNDATION HEALTH PLAN
INC., et al.,

20
21 Defendants.
22
23
24
25
26
27
28

Case No. 2:19-cv-0559-JAM-KJN

**DEFENDANTS' REPLY IN SUPPORT OF
MOTION TO DISMISS RELATOR'S FIRST
AMENDED COMPLAINT**

Hearing Date: October 18, 2022

Time: 1:30 p.m.

Judge: Hon. John A. Mendez

Courtroom: 6, 14th Floor

1 As the Motion to Dismiss (“Motion”) explained, Relator Jeffrey Mazik’s FAC does not
 2 make out any claim for relief.¹ His Opposition to Defendants’ Motion ignores many of
 3 Defendants’ arguments and legal citations, and like his FAC, relies on conclusory statements
 4 untethered to specific factual allegations. The Court should dismiss Mazik’s claims in full.

5 **I. The First-to-File Bar Requires Dismissal of Mazik’s FCA Fraud Claim**

6 The Court must dismiss Mazik’s federal FCA fraud claim (Count I) under the FCA’s
 7 jurisdictional first-to-file bar because Dr. James Taylor brought a *qui tam* action based on the
 8 same material facts as Mazik’s complaint years before Mazik did. Mot. at 7–10. In disputing that
 9 the first-to-file bar applies, Mazik relies heavily on *Osinek*’s holding that the first-filed complaint
 10 there did not bar certain allegations in the Taylor complaint. Opp’n at 4–5. But that holding is
 11 irrelevant here, where Taylor’s complaint is the first-filed complaint—instead, the Court must
 12 compare Taylor’s and Mazik’s complaints.²

13 Mazik has not pointed to any differences between his and Taylor’s complaints that would
 14 save his FCA fraud claim from dismissal under the first-to-file bar. In fact, Mazik concedes that
 15 his and Taylor’s complaints cover a similar geography and involve allegedly improper coding by
 16 external providers, which Mazik admits is a “*central component*” of the alleged fraud. Opp’n at
 17 8 (emphasis added). The only factual distinction Mazik attempts to make between the complaints
 18 is that his complaint focuses on “defunct compliance operations.” *Id.* at 8. But so does Taylor’s
 19 complaint, which alleges that Defendants failed to correct errors uncovered by audits, failed to
 20 conduct follow-up audits, and failed to utilize monitoring tools at Defendants’ disposal—and all
 21 with respect to external providers. Mot. at 9–10. Because Taylor alleges defunct compliance
 22 operations with respect to external providers, his complaint was sufficient to give the United
 23

24 ¹ Defendants attempted to file this Reply on September 26, 2022 but could not access the Eastern
 25 District’s e-filing system due to an apparent technical issue with the system. Accordingly,
 26 Defendants’ counsel sent the Reply to Mazik’s counsel by email on September 26 under Local
 27 Rule 134(c)(2). This Reply relies on the same abbreviations and acronyms as the Motion.

28 ² Mazik also misunderstands *Osinek*’s holding. See Opp’n at 6 n.7. Judge Chen granted the first-
 to-file motion in full with respect to the *Arefi*, *Stein*, and *Bicocca* complaints and dismissed
 claims in all of the later-filed complaints. *U.S. ex rel. Osinek v. Permanente Med. Grp.*, 2022 WL
 1422944, at *26 n.17, *29 (N.D. Cal. May 5, 2022). And Mazik ignores Judge Chen’s holding
 about the operative complaints for the first-to-file analysis, relying on citations to his FAC rather
 than his original complaint as required. See *id.* at *11; Mot. at 8 n.7.

1 States grounds to investigate Defendants’ oversight of external providers and discover Mazik’s
2 allegations. *Id.*; *see also U.S. ex rel. Batiste v. SLM Corp.*, 659 F.3d 1204, 1209 (D.C. Cir. 2011)
3 (first-to-file bar applied where “the allegations of the first complaint [gave] the government
4 grounds to investigate all that is in the second”); *Osinek*, 2022 WL 1422944, at *12 (similar and
5 collecting cases).

6 While Taylor does not describe the exact software that Mazik does, such a minor factual
7 difference cannot circumvent the first-to-file bar. The Ninth Circuit has rejected an identical facts
8 test; it is enough that Taylor’s and Mazik’s claims are based on the same material facts: that
9 Defendants failed to adequately monitor external-provider data. *See U.S. ex rel. Lujan v. Hughes*
10 *Aircraft Co.*, 243 F.3d 1181, 1189 (9th Cir. 2001) (noting that bar of “identical” actions would
11 “decrease incentives to promptly bring qui tam actions,” allow “recovery for the same conduct,”
12 and permit FCA claims to proceed that “have no additional benefit for the government” since the
13 first-filed action already gave the United States grounds to investigate the alleged fraud); *U.S. ex*
14 *rel. Branch Consultants v. Allstate Ins. Co.*, 560 F.3d 371, 378 (5th Cir. 2009) (“simply adding
15 factual details . . . to the essential or material elements of a fraud claim” will not save subsequent
16 *qui tam* complaint from dismissal under first-to-file bar); *Osinek*, 2022 WL 1422944, at *11, *26
17 (first-to-file bar applied where complaints alleged “the same kind of conduct”); *U.S. ex rel.*
18 *Marion v. Heald Coll., LLC*, 2015 WL 4512843, at *3 (N.D. Cal. July 24, 2015) (first-to-file bar
19 required dismissal of complaint that was “more detailed” than first-filed complaint but simply
20 alleged factual variation of same type of scheme).

21 **II. Mazik’s Federal FCA Fraud Claim Fails to Satisfy Rules 8 and 9(b)**

22 **Falsity.** The FAC does not plausibly allege that Defendants submitted a single false claim
23 to CMS. Mot. at 11–12. The Motion explains why each of Mazik’s falsity allegations is
24 deficient. *Id.* at 12–14. The Opposition largely glosses over this analysis and doubles down on
25 the allegation that Defendants disabled certain editing rules on the ClaimsXten compliance tool
26 that allegedly was used to evaluate claims data from the Georgia region. Opp’n at 12–13; FAC
27 ¶ 59. Merely alleging that Defendants disabled rules does not allege fraud with particularity—
28 Mazik does not allege what those disabled rules did or why disabling them lacked legitimate

1 reasoning. *See* Mot. at 11. Nor does it explain *how* disabling editing rules would result in the
 2 submission of false claims. *Id.* The Opposition argues that a different compliance software made
 3 by Verisk revealed “overpayments” that ClaimsXten did not, Opp’n at 13, but the FAC does not
 4 describe the Verisk software in any detail or allege what type of “overpayments” were
 5 identified—*e.g.*, whether the alleged overpayments resulted from false risk-adjustment data or
 6 what payer, if any, made the alleged overpayments. In any event, the FAC alleges that the Verisk
 7 tool was used on claims data from only the Georgia region; while Mazik names Colorado- and
 8 California-based entities as defendants, he names no Georgia-specific entities, so it is not clear on
 9 the face of the FAC which Defendant’s conduct could even be at issue. *See* FAC ¶¶ 58–59.

10 **Materiality.** The FAC’s bare recitation of the materiality standard without any factual
 11 support also fails to satisfy Rule 8 or 9(b). Mot. at 12–13; *see Universal Health Servs., Inc. v.*
 12 *United States*, 579 U.S. 176, 194 (2016). The Opposition does no better. It mentions materiality
 13 only once in a sentence full of legal conclusions: “the Complaint also sufficiently pleads ‘falsity’
 14 and ‘materiality’ via allegations describing how Kaiser knowingly submitted falsely inflated risk
 15 adjustment data . . . and knowingly received outsized capitation rate payments from the
 16 government as a result.” Opp’n at 14. Materiality, falsity, and knowledge are distinct elements,
 17 so whether any claims were false or submitted knowingly says nothing about CMS’s willingness
 18 to pay those claims—the key materiality question. *See* Mot. at 12.

19 **Conspiracy.** The Opposition does not address Defendants’ argument that Mazik fails to
 20 allege a conspiracy, *id.* at 13, so the Court should dismiss his conspiracy claims with prejudice.
 21 *Narang v. Gerber Life Ins. Co.*, 2018 WL 6728004, at *4 (N.D. Cal. Dec. 21, 2018) (collecting
 22 cases and observing that “[c]ourts have [] held that a plaintiff’s failure to oppose a defendant’s
 23 argument was a concession that such claims should be dismissed”); *see also* E.D. Cal. L.R. 230(c)
 24 (failure to file opposition may be construed as a non-opposition).

25 **III. Mazik’s State FCA Fraud Claims Fail to Satisfy Rules 8 and 9(b)³**

26 Mazik’s state FCA fraud claims fail not only for the same reasons that his federal FCA

27 _____
 28 ³ Mazik concedes that he must establish the same elements for his state FCA fraud claims as his
 federal FCA fraud claim. Opp’n at 14.

1 fraud claim fails, but also because they lack an adequate description of the relevant Medicaid
2 programs. While Mazik broadly alleges that state Medicaid programs operate on a similar
3 payment model as Medicare Advantage, FAC ¶ 33, the FAC lacks any material description of the
4 programs. Mazik does not describe Defendants’ business operations in any of the relevant states,
5 nor does he even allege that any Defendant contracts with any state Medicaid program. Mot. at
6 13. He similarly does not allege that any of the Defendant PMGs in California and Colorado
7 submitted claims to the out-of-state Medicaid programs at issue. Mazik argues that he need not
8 identify who submitted the claims to the Medicaid programs, Opp’n at 14–15, but as Mazik
9 himself recognizes, Rule 9(b) requires him to identify the “who” of any alleged fraud. *See id.* at
10 12–13. Given the FAC’s deficiencies, the Court cannot reasonably infer that any Defendant
11 submitted *any* claims—*false or otherwise*—to the state Medicaid programs at issue.

12 As the Motion argued, and the Opposition does not contest, Mazik also fails to describe
13 the compensation structure of the Medicaid programs, so he has not alleged the “how” of any
14 fraud on state entities. Mot. at 13–14; *see U.S. ex rel. Everest Principals, LLC v. Abbott Lab’y’s,*
15 *Inc.*, 2022 WL 3567063, at *9 (S.D. Cal. Aug. 18, 2022) (dismissing state FCA claims where
16 “Relator has not alleged with particularity *how* any false claims were submitted to *each* state
17 identified in the FAC” (emphases added)); *U.S. ex rel. Nowak v. Medtronic, Inc.*, 806 F. Supp. 2d
18 310, 357 (D. Mass. 2011) (dismissing state FCA claims where the relator did not “allege some
19 specificity with respect to *each* asserted state” (emphasis added)). This omission is fatal: without
20 allegations about how each state’s Medicaid program compensated Defendants, Mazik cannot
21 adequately allege FCA claims based on submissions to those programs. For example, the state
22 Medicaid programs may not use a risk-adjustment program similar to Medicare Advantage to
23 determine health plan payments. If the programs do not rely on diagnosis data to determine
24 payments, alleged errors in the data may not have been material to the programs’ payment
25 decisions.⁴

26
27 ⁴ The Opposition fails to address the argument that Mazik brought the Georgia claims under the
28 wrong statute. Mot. at 14 n. 11. The Court should dismiss Count IV for that reason alone. *See*
Narang, 2018 WL 6728004, at *4; E.D. Cal. L.R. 230(c).

1 **IV. Mazik’s Fraud Claims Fail Because They Rely on Improper Group Pleading**

2 Mazik cannot rely on group allegations to make out claims against each Defendant
3 because he alleges that Defendants serve different functions. One is a nonprofit health plan that
4 provides health coverage to members (KFHP); another is a nonprofit hospital (KFH); and the
5 others are geographically diverse, physician-run groups providing health care to unique member
6 populations (the PMGs). Mot. at 14. The Opposition cites *U.S. ex rel. Anita Silingo v. WellPoint,*
7 *Inc.*, 904 F.3d 667, 678 (9th Cir. 2018), but *Silingo* does not help Mazik. Opp’n at 15. *Silingo*
8 emphasized that collective allegations can satisfy pleading standards only where defendants
9 engaged in exactly the same conduct, but not where “different actors play[] different parts.” 904
10 F.3d at 677; *see also United States v. Prime Healthcare Servs. Inc.*, 2020 WL 11884833, at *5
11 (C.D. Cal. Apr. 14, 2020) (rejecting use of collective allegations where allegations showed
12 “independence within [the] corporate structure”). Given the different roles and functions of the
13 Defendants, Mazik cannot use collective allegations to satisfy pleading standards. Mot. at 14–15.

14 **V. Mazik’s Retaliation Claims Fail to Allege Notice of a Protected Activity**

15 The Opposition ignores Defendants’ argument that Mazik’s retaliation claims fail because
16 he does not identify which Defendant employed him. Mot. at 15. The Opposition also fails to
17 address Defendants’ argument that the FAC’s allegations do not support the inference that any
18 Defendant had notice that Mazik was engaged in a protected activity. *Id.* “If an employee’s job
19 duties include compliance and reporting,” as Mazik’s did, “that employee must suggest he intends
20 to bring an FCA claim or otherwise report the misconduct to the regulatory authority for an
21 employer to be sufficiently on notice[.]” *U.S. ex rel. Mooney v. Fife Dermatology, PC*, 2022 WL
22 3715763, at *2 (D. Nev. Aug. 29, 2022). Mazik has not attempted to allege any such facts.
23 Mazik instead argues that he needs to allege only that he believes he was terminated because of
24 his investigation into the practices specified in the complaint, citing *U.S. ex rel. Campie v. Gilead*
25 *Sciences, Inc.*, 862 F.3d 890, 909 (9th Cir. 2017). Opp’n at 12. But Mazik quotes *Campie*’s
26 discussion of the causation element of a retaliation claim, not what allegations are sufficient to
27 plead *notice* of the protected activity, which is the relevant element here. The Court should
28 dismiss the retaliation claims.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dated: September 27, 2022

Respectfully submitted,

By: /s/ Dimitri D. Portnoi
DIMITRI D. PORTNOI
KYLE M. GROSSMAN

*Attorneys for Defendants Kaiser
Foundation Health Plan, Inc.; Kaiser
Foundation Hospitals; The Permanente
Medical Group, Inc.; Southern
California Permanente Medical Group;
and Colorado Permanente Medical
Group, P.C.*